Bli medlem
Bli medlem

Du är här

2020-08-14

ViroGates A/S: Västra Hamnen: ViroGates - Steadily growing customer base

  • Increasing attention on efficient triaging due to COVID-19 pandemic
  • Currently ten clinical routine customers
  • We keep our valuation interval unchanged at DKK 68.00 - 100.50 per share

ViroGates' report for Q2 2020 came in almost exactly in line with our forecasts.
Revenues, although markedly lower than a year ago, were precisely
as expected. The cost side came in a little lower than our forecasts, resulting
in a lower net loss compared with our estimates. The revenue drop was
related to a well-known problem at one customer hospital. Apart from
that, the underlying business development is progressing fairly well considering
the COVID-19 situation. If anything, the pandemic seems to increase
interest in the suPARnostic® products.
The full report is available here (https://www.vhcorp.se/uploads/1525_Virogates_update_200814.pdf?pdf=Virogates_update_200814.pdf).

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)

Författare ViroGates A/S

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.